Alzheimer's disease and age-related memory decline (preclinical)
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
An unfortunate result of the rapid rise in geriatric populations worldwide is the increasing prevalence of age-related cognitive disorders such as Alzheimer’s disease (AD). AD is a devastating neurodegenerative illness that is characterized by a profound impairment of cognitive function, marked physical disability, and an enormous economic burden on the afflicted individual, caregivers, and society in general. The rise in elderly populations is also resulting in an increase in individuals with related (potentially treatable) conditions such as “Mild Cognitive Impairment” (MCI) which is characterized by a less severe (but abnormal) level of cognitive impairment and a high-risk for developing dementia. Even in the absence of a diagnosable disorder of cognition (e.g., AD, MCI), the perception of increased forgetfulness and declining mental function is a clear source of apprehension in the elderly. This is a valid concern given that even a modest impairment of cognitive function is likely to be associated with significant disability in a rapidly evolving, technology-based society. Unfortunately, the currently available therapies designed to improve cognition (i.e., for AD and other forms of dementia) are limited by modest efficacy, adverse side effects, and their effects on cognitive function are not sustained over time. Accordingly, it is incumbent on the scientific community to develop safer and more effective therapies that improve and/or sustain cognitive function in the elderly allowing them to remain mentally active and productive for as long as possible. As diagnostic criteria for memory disorders evolve, the demand for pro-cognitive therapeutic agents is likely to surpass AD and dementia to include MCI and potentially even less severe forms of memory decline. The purpose of this review is to provide an overview of the contemporary therapeutic targets and preclinical pharmacologic approaches (with representative drug examples) designed to enhance memory function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Alzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168
Mammalian nicotinic acetylcholine receptors: from structure to function
Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., & Rogers, S. W. (2009) · Physiological Reviews · doi:10.1152/physrev.00015.2008 · Cited by 1,724
The role of acetylcholine in learning and memory
Hasselmo, M. E. (2006) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2006.09.002 · Cited by 1,693
HDAC2 negatively regulates memory formation and synaptic plasticity
Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature · doi:10.1038/nature07925 · Cited by 1,644
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261 · cited 1×
“On an individual level, AD significantly shortens life expectancy and it is one of the major causes of physical disability, institutionalization, and decreased quality of life among the elderly (reviewed Qiu et al., 2009).”
BackgroundEffects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons
Frey, U., Huang, Y.-Y., & Kandel, E. R. (1993) · Science · doi:10.1126/science.8389057 · Cited by 1,218 · cited 2×
“Activation of the cAMP/PKA/CREB and cGMP/PKG/CREB pathway has been implicated in synaptic plasticity such as long-term potentiation (LTP) and cognitive function (Frey et al., 1993; Son et al., 1998; Blokland et al., 2006).”
BackgroundTerry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159
Self-citationPhysiological Diversity of Nicotinic Acetylcholine Receptors Expressed by Vertebrate Neurons
McGehee, D. S., & Role, L. W. (1995) · Annual Review of Physiology · doi:10.1146/annurev.ph.57.030195.002513 · Cited by 1,022 · cited 1×
“Nicotinic receptors are composed of five membrane-spanning subunits that form a pentameric arrangement around a water-filled pore (Jones et al., 1999; Karlin 2002; McGehee and Role, 1995).”
BackgroundMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Cited by
Kouémou, N. E., Taiwe, G. S., Moto, F. C. O., Pale, S., Ngoupaye, G. T., Njapdounke, J. S. K., Nkantchoua, G. C. N., Pahaye, D. B., & Bum, E. N. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00847 · Cited by 55
Yadav, M. K., Singh, S. K., Singh, M., Mishra, S. S., Singh, A. K., Tripathi, J. S., & Tripathi, Y. B. (2019) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2019.247 · Cited by 26
“Alzheimer’s disease is a progressive neurodegenerative disease which is characterised by the loss of learning and memory abilities with ageing [1].”
BackgroundHosseini, Z., Mansouritorghabeh, F., Kakhki, F. S. H., Hosseini, M., Rakhshandeh, H., Hosseini, A., Hasanpour, M., Iranshahi, M., & Rajabian, A. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-021-00898-y · Cited by 24
Metadata
- Authors
- Terry, A. V., Callahan, P. M., Hall, B., & Webster, S. J.
- Venue
- Pharmacology Biochemistry and Behavior
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 99
- Issue
- 2
- Pages
- 190-210
- ISSN
- 0091-3057 (ISSN-L)
- OpenAlex
- W2026305700
- Cited by
- 86
- References
- 38
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alzheimer's disease and age-related memory decline (preclinical). https://app.cochat.ai/papers/10.1016/j.pbb.2011.02.002
- The paper
- Terry, A. V., Callahan, P. M., Hall, B., & Webster, S. J. (2011). Alzheimer's disease and age-related memory decline (preclinical). Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2011.02.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.